Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Harrington, Robert
One or more keywords matched the following items that are connected to Harrington, Robert
Item TypeName
Concept Antibodies, Monoclonal
Academic Article Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
Academic Article Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Academic Article Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
Academic Article Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
Academic Article Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Academic Article Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Academic Article Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Academic Article Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Academic Article Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Academic Article Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial.
Academic Article Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Academic Article Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Academic Article Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Academic Article Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Academic Article Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Academic Article Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Academic Article Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Academic Article Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Academic Article Canakinumab for Atherosclerotic Disease.
Academic Article Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Academic Article Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Academic Article Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
Academic Article Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome.
Academic Article Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES.
Academic Article Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Concept Antibodies, Monoclonal, Humanized
Academic Article Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Academic Article Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
Search Criteria
  • Antibodies